Idiopathic Pulmonary Fibrosis research hub

Changes in iOS in IPF

This study looks at a new way to measure lung health in people with Idiopathic Pulmonary Fibrosis (IPF). It explores if a test called impulse oscillometry (iOS) can give clear, useful information about how IPF affects the lungs and predict if it might get worse, potentially making monitoring easier.

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

This study looks into a new drug called Senicapoc for people with lung scarring diseases like pulmonary fibrosis. Researchers want to see if Senicapoc can stop the scarring from getting worse, compared to a dummy pill. It involves taking pills for 26 weeks and having check-ups.

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

This study is testing a new medicine, ENV-101, for people with lung scarring conditions like Idiopathic Pulmonary Fibrosis (IPF). It aims to see if it improves breathing and is safe to use. Patients might continue their usual treatments.

Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank

This study collects information and samples from people with rare lung conditions, including Idiopathic Pulmonary Fibrosis (IPF). It aims to understand these diseases better and help find new treatments. It's a Europe-wide effort to improve care for patients.

Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

This study looks at whether a stomach acid medicine, lansoprazole, can help people with Idiopathic Pulmonary Fibrosis (IPF). IPF causes lung scarring, and stomach acid reflux might make it worse. We want to see if this medicine can slow down IPF progression and help patients feel better.

NAL ER IPF Respiratory Function and Safety Study

This study is looking at a new medicine called NAL ER for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medicine is safe, what doses people can tolerate, and if it helps with breathing.

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

This study is testing a new medicine, PIPE-791, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). We want to see how well it works, if it's safe, and if people can tolerate it. It's a phase 2 study, meaning we're still in the early stages of testing.

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

This study, called WISPer, is testing a new medicine called MTX-463 for Idiopathic Pulmonary Fibrosis (IPF). It's comparing MTX-463 to a dummy medicine (placebo) to see if it's safe and effective for people with this lung condition.

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

This study is testing a new medicine called CAL101 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if CAL101 can help stop lungs from getting worse in adults with IPF, compared to a dummy treatment.

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

This study is looking at a new medicine called axatilimab for people with Idiopathic Pulmonary Fibrosis (IPF). We want to see if it's safe and effective in slowing down this lung condition. It's a Phase 2 trial, meaning it's still in earlier stages of testing.

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

This study is looking at a new medicine called BMS-986278 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to see how well it works, if it's safe, and if people can tolerate it.

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis

This study is looking into new treatments for Idiopathic Pulmonary Fibrosis (IPF), a serious lung condition. Researchers will compare a new medicine with a dummy treatment to see if it can improve lung function over 24 weeks. It's for adults with IPF.

A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of MBS2320 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.

A participant - and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in patients with idiopathic pulmonary fibrosis

Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial. PROGRESSION-IPF

A Phase 2, randomized, double-blind, placebo-controlled, parallel group study (TRANSFORM) to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

Proof-of-principle study of inhaled pulmonary surfactant in patients with Idiopathic Pulmonary Fibrosis (INSURF-IPF)

A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)

Evaluation of the value of 18F-Fluoromisonidazole (18F-FMISO) positron emission tomography hypoxia imaging in idiopathic pulmonary fibrosis - A non-randomized proof-of-concept study comparing patients with idiopathic pulmonary fibrosis and healthy subjects